<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article239</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/RE-COVER" style="display:block; margin-bottom:10px;">RE-COVER Original</a></li>
<h2><strong>RE-COVER</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism". The New England Journal of Medicine. 2009. 361(24):2342-2352. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with acute venous thromboembolism, is dabigatran an effective alternative to warfarin for anticoagulation?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with acute venous thromboembolism, dabigatran was found to be noninferior to warfarin in terms of preventing recurrent events, had a similar safety profile, and did not require laboratory monitoring.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Warfarin has been the mainstay therapy for venous thromboembolism but requires frequent INR monitoring and dietary restrictions. Dabigatran, a direct thrombin inhibitor, may offer an easier-to-use alternative without needing routine blood coagulation testing.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
No guidelines were provided within this article.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Randomized, double-blind, double-dummy, noninferiority trial comparing dabigatran with warfarin following initial parenteral anticoagulation therapy. Each patient received 6 months of treatment.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
A total of 2,564 patients with acute venous thromboembolism:<br/>
- Inclusion criteria: Adults ≥18 years with acute proximal deep-vein thrombosis of the legs or pulmonary embolism requiring 6 months of anticoagulation<br/>
- Exclusion criteria: Prolonged (&gt;14 days) symptoms, hemodynamically unstable pulmonary embolism requiring thrombolysis, other indications for warfarin, recent unstable cardiovascular disease, high risk of bleeding, severe liver disease, creatinine clearance &lt;30 ml/min, pregnancy or risk of pregnancy, and long-term antiplatelet therapy<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Dabigatran (150 mg twice daily) after initial parenteral anticoagulation<br/>
- Warfarin (dose-adjusted to achieve INR 2.0-3.0) after initial parenteral anticoagulation<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome: Frequency of recurrent symptomatic, objectively confirmed venous thromboembolism and related deaths over 6 months<br/>
- Safety end points: Bleeding episodes, acute coronary syndromes, other adverse events, liver function tests<br/>
- Dabigatran group had 30 events (2.4%) vs. 27 events (2.1%) in the warfarin group<br/>
- Hazard ratio for dabigatran was 1.10 (95% CI, 0.65 to 1.84), meeting criteria for noninferiority (P&lt;0.001)<br/>
- Major bleeding: 20 cases (1.6%) in dabigatran group vs. 24 cases (1.9%) in warfarin group (hazard ratio 0.82; 95% CI, 0.45 to 1.48)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- First dose of dabigatran was only given after initial parenteral anticoagulation therapy for a median of 9 days; no evidence for monotherapy use at the acute phase<br/>
- The study's population was predominantly white and had good renal function, limiting generalizability<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Boehringer Ingelheim (manufacturer of dabigatran).<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
ClinicalTrials.gov number, NCT00291330.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
